Your browser doesn't support javascript.
Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance.
König, Christina; Both, Anna; Rohde, Holger; Kluge, Stefan; Frey, Otto R; Röhr, Anka C; Wichmann, Dominic.
  • König C; Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
  • Both A; Department of Pharmacy, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
  • Rohde H; Department of Microbiology, University Medical Center Hamburg-Eppendorf, Virology and Hygiene, 20251 Hamburg, Germany.
  • Kluge S; Department of Microbiology, University Medical Center Hamburg-Eppendorf, Virology and Hygiene, 20251 Hamburg, Germany.
  • Frey OR; Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
  • Röhr AC; Department of Pharmacy, General Hospital of Heidenheim, 89522 Heidenheim, Germany.
  • Wichmann D; Department of Pharmacy, General Hospital of Heidenheim, 89522 Heidenheim, Germany.
Antibiotics (Basel) ; 10(6)2021 May 28.
Article in English | MEDLINE | ID: covidwho-1285366
ABSTRACT
Cefiderocol is a new siderophore-cephalosporin for the treatment of multi-drug resistant Gram-negative pathogens. As a reserve agent, it will and should be used primarily in critically ill patients in the upcoming years. Due to the novelty of the substance little data on the pharmacokinetics in critically ill patients with septic shock and renal failure (including continuous renal replacement therapy and cytokine adsorber therapy) is available. We performed therapeutic drug monitoring in a cohort of five patients treated with cefiderocol, to improve the knowledge on pharmacokinetics in this vulnerable patient population. As expected for a cephalosporin with predominantly renal elimination the maintenance dose could be reduced in patients with renal impairment or on continuous renal replacement therapy. The manufacturer's dosing instructions were sufficient to achieve a drug level well above the MIC. However, the addition of a cytokine adsorber might reduce serum levels substantially, so that in this context therapeutic drug monitoring and dose adjustment are recommended.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: Antibiotics10060649

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: Antibiotics10060649